Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Depression is one of the most common mental illness in the United States. It affects more than 20 million people a year.

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

New research highlights how the brain's reward-learning system can guide personalized treatments for depression.

Depression is a condition that casts a shadow over the lives of many, with one in five Australians experiencing its grip at ...

The research, published today in the peer-reviewed journal Bioelectronic Medicine, was commissioned by Convergent Research, a ...